U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula O4S.Zn.H2O
Molecular Weight 179.487
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC SULFATE MONOHYDRATE

SMILES

O.[Zn++].[O-]S([O-])(=O)=O

InChI

InChIKey=RNZCSKGULNFAMC-UHFFFAOYSA-L
InChI=1S/H2O4S.H2O.Zn/c1-5(2,3)4;;/h(H2,1,2,3,4);1H2;/q;;+2/p-2

HIDE SMILES / InChI

Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula HO4S
Molecular Weight 97.071
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Zinc monocarbonate (Zinc Carbonate) is an inorganic salt. In the United States, Zinc Carbonate may be used as an active ingredient in OTC drug products. When used as an active drug ingredient, the established name is Zinc Carbonate. Zinc monocarbonate is generally recognized as safe by FDA. It is used as skin protectant active ingredient. Zinc carbonate was found to retard the degradation of some poly(lactide-co-glycolide) (PLG) microspheres in vivo and in vitro. Adding Zinc Carbonate is essential during the preparation of PLGA microspheres. It can remarkably improve the stability of drugs in the acid microenvironment inside PLGA microspheres.

CNS Activity

Curator's Comment: Spatial memory deficits in a mouse model of late-onset Alzheimer's disease were caused by Zinc Carbonate supplementation. Long-term dietary administration of zinc ( Zinc Carbonate) can lead to impairments in cognitive function in rats. Microprobe synchrotron X-ray fluorescence (microSXRF) confirmed that brain zinc levels were increased by adding Zinc Carbonate to the drinking water.

Originator

Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

1955
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Secondary
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

2012
Primary
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

2006
Primary
ZINC OXIDE

Approved Use

Unknown
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
PubMed

PubMed

TitleDatePubMed
A medicated polycarboxylate cement to prevent complications in composite resin therapy.
1990 Jan
Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds.
1994 Dec
New applications for the zinc iodide-osmium tetroxide technique.
1994 Feb
Enantioselective Cyclopropanation of Allylic Alcohols. The Effect of Zinc Iodide.
1997 May 16
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.
1999 Spring
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats.
2000 Sep
On the mechanism of the conversion of methanol to 2,2,3-trimethylbutane (triptane) over zinc iodide.
2006 Nov 10
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing.
2010 Dec
In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles.
2010 Dec 1
Role of the dissolved zinc ion and reactive oxygen species in cytotoxicity of ZnO nanoparticles.
2010 Dec 15
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.
2010 Feb
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells.
2010 Jan 12
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.
2010 Jul
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway.
2010 Oct
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways.
2011 Dec
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.
2011 Jul
Titanium oxide shell coatings decrease the cytotoxicity of ZnO nanoparticles.
2011 Mar 21
Responses of human cells to ZnO nanoparticles: a gene transcription study.
2011 Nov
Zinc induces chemokine and inflammatory cytokine release from human promonocytes.
2011 Nov 30
Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study.
2011 Sep
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity.
2012 Feb
Aerosolized ZnO nanoparticles induce toxicity in alveolar type II epithelial cells at the air-liquid interface.
2012 Feb
Association of zinc ion release and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung.
2012 Jun 25
Zinc oxide nanoparticles-induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells.
2012 Mar
Molecular cloning, characterization of copper/zinc superoxide dismutase and expression analysis of stress-responsive genes from Eisenia fetida against dietary zinc oxide.
2012 Mar
Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts.
2012 May 5
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.
2013 Dec
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013 Jan
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.
2013 Jul 31
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.
2013 Mar
Inorganic salts in atmospheric particulate matter: Raman spectroscopy as an analytical tool.
2013 Nov
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation.
2013 Sep
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.
2014 Apr
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.
2014 Jan
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.
2014 Jul 1
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.
2014 Mar 3
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.
2014 May 16
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition.
2014 May 16
ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice.
2014 Nov 4
Ultrasonic assisted removal of sunset yellow from aqueous solution by zinc hydroxide nanoparticle loaded activated carbon: Optimized experimental design.
2015
Endoplasmic reticulum stress and oxidative stress are involved in ZnO nanoparticle-induced hepatotoxicity.
2015 Apr 2
Synthesis aspects, structural, spectroscopic, antimicrobial and room temperature ferromagnetism of zinc iodide complex with Schiff based ligand.
2015 Jan 25
Simultaneous sulfate and zinc removal from acid wastewater using an acidophilic and autotrophic biocathode.
2016 Mar 5
Spectroscopic probe to contribution of physicochemical transformations in the toxicity of aged ZnO NPs to Chlorella vulgaris: new insight into the variation of toxicity of ZnO NPs under aging process.
2016 Oct
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.
2016 Oct 1
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.
2016 Sep
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.
2016 Sep 21
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass.
2017 May 15
Patents

Sample Use Guides

Rats: The dosage of zinc fluoride tetrahydrate (ZnF2 •4H2O) was adjusted to contain 2.1 mg (low-dose group, LG), 4.3 mg (mid-dose group, MG), and 5.4 mg fluoride per 200 g rat body weight (high-dose group, HG) corresponding to 5, 10, and 12.5 % of LD50 values for NaF.
Route of Administration: Oral
In Vitro Use Guide
Prepared ground human enamel specimens were immersed in zinc fluoride solutions containing 250 and 750 ppm F- at pH 6 and 4 for 4 min.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:17:22 GMT 2023
Edited
by admin
on Fri Dec 15 16:17:22 GMT 2023
Record UNII
PTX099XSF1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINC SULFATE MONOHYDRATE
EP   MI   VANDF   WHO-DD   WHO-IP  
Systematic Name English
ZINCI SULFAS MONOHYDRATE [WHO-IP LATIN]
Common Name English
ZINC SULFATE MONOHYDRATE [EP MONOGRAPH]
Common Name English
ZINC SULFATE MONOHYDRATE [MI]
Common Name English
ZINC SULPHATE (1:1) MONOHYDRATE
Common Name English
ZINC SULFATE (1:1) MONOHYDRATE
Common Name English
SULFURIC ACID, ZINC SALT (1:1), MONOHYDRATE
Common Name English
ZINC SULFATE (MONOHYDRATE)
Systematic Name English
ZINC SULPHATE MONOHYDRATE
Systematic Name English
ZINC SULFATE MONOHYDRATE [WHO-IP]
Common Name English
ZINC SULFATE MONOHYDRATE [USP MONOGRAPH]
Common Name English
ZINC SULFATE MONOHYDRATE [VANDF]
Common Name English
ZINC SULPHATE (MONOHYDRATE)
Systematic Name English
Zinc sulfate monohydrate [WHO-DD]
Common Name English
ZINC SULFATE [WHO-IP]
Common Name English
Classification Tree Code System Code
EPA PESTICIDE CODE 527200
Created by admin on Fri Dec 15 16:17:22 GMT 2023 , Edited by admin on Fri Dec 15 16:17:22 GMT 2023
Code System Code Type Description
EVMPD
SUB22913
Created by admin on Fri Dec 15 16:17:22 GMT 2023 , Edited by admin on Fri Dec 15 16:17:22 GMT 2023
PRIMARY
DAILYMED
PTX099XSF1
Created by admin on Fri Dec 15 16:17:22 GMT 2023 , Edited by admin on Fri Dec 15 16:17:22 GMT 2023
PRIMARY
DRUG BANK
DBSALT001304
Created by admin on Fri Dec 15 16:17:22 GMT 2023 , Edited by admin on Fri Dec 15 16:17:22 GMT 2023
PRIMARY
NCI_THESAURUS
C45678
Created by admin on Fri Dec 15 16:17:22 GMT 2023 , Edited by admin on Fri Dec 15 16:17:22 GMT 2023
CONCEPT Industrial Aid
PUBCHEM
62639
Created by admin on Fri Dec 15 16:17:22 GMT 2023 , Edited by admin on Fri Dec 15 16:17:22 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ZINC SULFATE MONOHYDRATE
Created by admin on Fri Dec 15 16:17:22 GMT 2023 , Edited by admin on Fri Dec 15 16:17:22 GMT 2023
PRIMARY Description: A white or almost white, crystalline powder, or colourless, transparent crystals. Solubility: Very soluble in water, practically insoluble in ethanol (~750 g/l) TS. Category: Adjunct to oral rehydration salts in( prevention and) treatment of dehydration due to diarrhoea; astringent. Storage: Zinc sulfate should be kept in a well-closed, non-metallic container. Labelling: The designation on the container should state whether the substance is in the monohydrate or heptahydrate form and, where appropriate, that it is suitable for use in the manufacture of parenteral dosage forms. Definition: Zinc sulfate monohydrate contains not less than 99.0% and not more than 101.0% of ZnSO4,H2O. Zinc sulfate heptahydrate contains not less than 99.0% and not more than 104.0% of ZnSO4,7H2O.
RXCUI
1309410
Created by admin on Fri Dec 15 16:17:22 GMT 2023 , Edited by admin on Fri Dec 15 16:17:22 GMT 2023
PRIMARY RxNorm
EPA CompTox
DTXSID2035019
Created by admin on Fri Dec 15 16:17:22 GMT 2023 , Edited by admin on Fri Dec 15 16:17:22 GMT 2023
PRIMARY
CAS
7446-19-7
Created by admin on Fri Dec 15 16:17:22 GMT 2023 , Edited by admin on Fri Dec 15 16:17:22 GMT 2023
PRIMARY
SMS_ID
100000087994
Created by admin on Fri Dec 15 16:17:22 GMT 2023 , Edited by admin on Fri Dec 15 16:17:22 GMT 2023
PRIMARY
NCI_THESAURUS
C75660
Created by admin on Fri Dec 15 16:17:22 GMT 2023 , Edited by admin on Fri Dec 15 16:17:22 GMT 2023
PRIMARY
RS_ITEM_NUM
1724769
Created by admin on Fri Dec 15 16:17:22 GMT 2023 , Edited by admin on Fri Dec 15 16:17:22 GMT 2023
PRIMARY
FDA UNII
PTX099XSF1
Created by admin on Fri Dec 15 16:17:22 GMT 2023 , Edited by admin on Fri Dec 15 16:17:22 GMT 2023
PRIMARY
MERCK INDEX
m11629
Created by admin on Fri Dec 15 16:17:22 GMT 2023 , Edited by admin on Fri Dec 15 16:17:22 GMT 2023
PRIMARY Merck Index
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY